Published in Neuropharmacology on January 01, 1998
Genetic knockout and pharmacologic inhibition of neuronal nitric oxide synthase attenuate nerve injury-induced mechanical hypersensitivity in mice. Mol Pain (2007) 1.37
A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol (2000) 1.05
Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol (1999) 1.04
Nitric oxide synthase modulates CFA-induced thermal hyperalgesia through cytokine regulation in mice. Mol Pain (2010) 1.00
Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. Br J Pharmacol (2002) 0.90
Antagonism of the antinociceptive effect of nitrous oxide by inhibition of enzyme activity or expression of neuronal nitric oxide synthase in the mouse brain and spinal cord. Eur J Pharmacol (2009) 0.80
Anti-inflammatory and anti-hyperalgesic effect of all-trans retinoic acid in carrageenan-induced paw edema in Wistar rats: involvement of peroxisome proliferator-activated receptor-β/δ receptors. Indian J Pharmacol (2013) 0.80
Co-induction of cyclooxygenase-2 [correction of cyclooxyenase-2] and early growth response gene (Egr-1) in spinal cord in a clinical model of persistent inflammation and hyperalgesia. Mol Pain (2011) 0.79
Nitric oxide modulates the hyperalgesic response to mechanical noxious stimuli in sleep-deprived rats. BMC Neurosci (2013) 0.75
Role of nitric oxide synthase in the development of bone cancer pain and effect of L‑NMMA. Mol Med Rep (2015) 0.75
L-NG-monomethyl arginine and L-NG-nitro arginine inhibit non-adrenergic, non-cholinergic relaxation of the mouse anococcygeus muscle. Br J Pharmacol (1990) 2.84
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
The smooth muscle relaxant effect of hydrogen sulphide in vitro: evidence for a physiological role to control intestinal contractility. Br J Pharmacol (2002) 2.05
Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends Pharmacol Sci (2008) 1.84
Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol (2006) 1.68
Endothelium-derived relaxing factor and the effects of acetylcholine and histamine on resistance blood vessels. Br J Pharmacol (1988) 1.59
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. Neuroreport (1994) 1.56
Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol (1978) 1.47
Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol (1993) 1.47
A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity. Br J Pharmacol (1998) 1.41
Pathways of prostaglandin F2alpha metabolism in mammalian kidneys. Br J Pharmacol (1977) 1.40
An investigation of some S-nitrosothiols, and of hydroxy-arginine, on the mouse anococcygeus. Br J Pharmacol (1992) 1.33
The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol (1991) 1.28
Anti-inflammatory steroids reduce tissue PG synthetase activity and enhance PG breakdown. Nature (1980) 1.22
Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur J Pharmacol (1988) 1.21
Synergistic anti-nociceptive effect of L-NG-nitro arginine methyl ester (L-NAME) and flurbiprofen in the mouse. Br J Pharmacol (1992) 1.14
Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol (1980) 1.11
Pathophysiological states modify levels in rat plasma of factors which inhibit synthesis and enhance breakdown of PG. Nature (1980) 1.08
Anode/cathode make and break phenomena in a model of defibrillation. IEEE Trans Biomed Eng (1999) 1.08
Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol (2002) 1.08
7-Nitro indazole derivatives are potent inhibitors of brain, endothelium and inducible isoforms of nitric oxide synthase. Life Sci (1995) 1.07
A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol (2000) 1.05
Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br J Pharmacol (2000) 1.04
Hydrogen sulphide is pro-inflammatory in haemorrhagic shock. Inflamm Res (2008) 1.02
An overview of the biological significance of endogenous gases: new roles for old molecules. Biochem Soc Trans (2007) 1.01
The effect of arginine and nitric oxide on resistance blood vessels of the perfused rat kidney. Br J Pharmacol (1989) 1.01
Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung. Br J Pharmacol (1986) 0.99
Inhibition of nitric oxide synthase--potential for a novel class of therapeutic agent? Trends Biotechnol (1995) 0.98
A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol (2001) 0.97
Human plasma contains prostaglandin 'reciprocal coupling factor'. Eur J Pharmacol (1980) 0.97
The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. Br J Pharmacol (1995) 0.95
A nociceptive-intensity-dependent role for hydrogen sulphide in the formalin model of persistent inflammatory pain. Neuroscience (2008) 0.94
Essential role for nitric oxide in neurogenic inflammation in rat cutaneous microcirculation. Evidence for an endothelium-independent mechanism. Circ Res (1995) 0.91
Prostaglandins and mechanism of action of sulphasalazine in ulcerative colitis. Lancet (1978) 0.90
Increased vasodilator response to acetylcholine of renal blood vessels from diabetic rats. J Pharm Pharmacol (1988) 0.90
Anti-nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of L-NAME and L-NMMA. J Pharm Pharmacol (1993) 0.89
Hydrogen sulphide in the hypothalamus causes an ATP-sensitive K+ channel-dependent decrease in blood pressure in freely moving rats. Neuroscience (2008) 0.88
Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Br J Pharmacol (1995) 0.87
Pre-synaptic and post-synaptic effects of xylazine and naphazoline on the bisected rat vas deferens. Arch Int Pharmacodyn Ther (1982) 0.85
Prostaglandin metabolism in rabbit kidney. Identification and properties of a novel prostaglandin 9-hydroxydehydrogenase. Biochim Biophys Acta (1978) 0.85
Effect of 6 keto-prostaglandin E on sympathetic neurotransmission in the vas deferens. J Pharm Pharmacol (1983) 0.85
An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol (1995) 0.85
On the effect of sulphasalazine on the prostaglandin system and the defective prostaglandin inactivation observed in experimental ulcerative colitis. Agents Actions Suppl (1979) 0.83
Mechanism of the inhibition of neuronal nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM). Life Sci (1997) 0.82
Formation of 6-keto prostaglandin E1 in mammalian kidneys. Br J Pharmacol (1983) 0.82
Selective actions of aspirin- and sulphasalazine-like drugs against prostaglandin synthesis and breakdown. Biochem Pharmacol (1982) 0.82
Synergism between prostacyclin (PGI2) and prazosin on human platelet aggregation. Thromb Haemost (1982) 0.82
Prostaglandin synthesis and inactivation in kidneys and lungs of rats with experimental diabetes. Clin Sci (Lond) (1980) 0.81
Enzymatic inactivation of 6-keto-prostaglandin E1 in vitro: comparison with prostaglandin E1. Biochem Pharmacol (1984) 0.80
Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance. Br J Pharmacol (2014) 0.80
Flurbiprofen and its nitric oxide-releasing derivative protect against septic shock in rats. Inflamm Res (2006) 0.80
Release of a 6-oxoprostaglandin E1-like substance from human platelets. Clin Sci (Lond) (1983) 0.80
Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects. Br J Pharmacol (1996) 0.79
Inhibition of nitric oxide synthase by isothioureas: cardiovascular and antinociceptive effects. Pharmacol Biochem Behav (1996) 0.79
Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol (2001) 0.79
Age-dependent changes in the synthesis and catabolism of 6 oxo PGE1 and other prostanoids by the rat kidney in vitro. Biochem Pharmacol (1985) 0.79
Release of biologically active substances from non-aggregating human platelets. Eur J Pharmacol (1982) 0.79
Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets. Br J Pharmacol (1983) 0.78
The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1. Biochem Pharmacol (1983) 0.78
Effect of peroxynitrite on plasma extravasation, microvascular blood flow and nociception in the rat. Br J Pharmacol (1997) 0.78
Review: 6 keto-prostaglandin-E1. Prostaglandins (1983) 0.78
Effect of a nitric oxide releasing derivative of paracetamol in a rat model of endotoxaemia. Br J Pharmacol (2006) 0.78
Sulphasalazine inhibits the pulmonary inactivation of prostaglandins in the rat in vivo [proceedings]. Br J Pharmacol (1979) 0.78
Augmented antinociception following 7-nitro indazole and flurbiprofen in the conscious mouse. Eur J Pharmacol (1994) 0.78
Distribution of four prostaglandin-metabolising enzymes in organs of the rabbit. Biochem Pharmacol (1978) 0.77
L-NG-nitro arginine p-nitroanilide (L-NAPNA) is anti-nociceptive in the mouse. Neuroreport (1993) 0.77
Nicotine causes prostaglandin efflux from isolated perfused rat lung [proceedings]. Br J Pharmacol (1979) 0.77
Neurogenic oedema and vasodilatation: effect of a selective neuronal NO inhibitor. Neuroreport (1998) 0.77
Effect of 7-nitro indazole on neurotransmission in the rat vas deferens: mechanisms unrelated to inhibition of nitric oxide synthase. Br J Pharmacol (1994) 0.77
Amino acids dilate resistance blood vessels of the perfused rat mesentery. J Pharm Pharmacol (1989) 0.77
Prostaglandins release plasma 'reciprocal coupling factor' in anaesthetized rats. Br J Pharmacol (1981) 0.75
Thyroxine-induced hyperthyroid state in rats suppresses renal prostaglandin metabolism [proceedings]. Br J Pharmacol (1978) 0.75
Enzyme in rabbit kidney converts prostaglandin F2alpha directly to prostaglandin E2 in vitro [proceedings]. Br J Pharmacol (1978) 0.75
Nitric oxide homeostasis control as therapy for cardiovascular diseases. Cardiovasc Res (1993) 0.75
Sympathomimetic amine-induced potentiation of fibrinolytic activity is partly modulated by endogenous prostaglandins in the rat. Thromb Res (1989) 0.75
The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro. J Pharm Pharmacol (1985) 0.75
Catabolism of 6 keto PGE1: biological activation by the rat kidney in vitro. Eur J Pharmacol (1983) 0.75
Experimental hyperthyroidism in rats suppresses in vitro prostaglandin metabolism in lung and kidney. Prostaglandins (1978) 0.75
Sulphasalazine analogue Ph CH 44A: powerful and selective inhibitor of prostaglandin breakdown in vitro and in vivo. Eur J Pharmacol (1980) 0.75
Interaction of prostaglandins and clonidine in the rat vas deferens. J Pharm Pharmacol (1982) 0.75
Ethical dilemmas in reproductive medicine. Whittier Law Rev (1996) 0.75
Effect of aspirin treatment on the hypotensive effect of clonidine in rats. Arch Int Pharmacodyn Ther (1983) 0.75
Novel actions of anti-inflammatory steroids on the prostaglandin system. Agents Actions Suppl (1980) 0.75
Sulphasalazine increases fibrinolysis in the anaesthetised rat. Thromb Haemost (1988) 0.75
Sulphinpyrazone inhibits platelet function and enhances blood fibrinolytic activity in the rat. Thromb Res (1988) 0.75